Characterization of the incretin response and microbiota following bariatric surgery, and its role for weight loss – a search for polytherapeutic strategies to combat obesity and ultimately rival surgery

Submission date 27/02/2017	Recruitment status No longer recruiting	 Prospectively registered Protocol
Registration date 03/04/2017	Overall study status Completed	 Statistical analysis plan Results
Last Edited 06/03/2019	Condition category Nutritional, Metabolic, Endocrine	Individual participant dataRecord updated in last year

Plain English summary of protocol

Background and study aims

Obesity represents a global epidemic, and increases the risk of developing Type 2 Diabetes Mellitus (T2DM), hence the introduction of the term "diabesity". The most effective and longlasting solution for severe obesity is bariatric surgery. Two widely used types of bariatric surgery are gastric bypass and gastric sleeve. Gastric bypass involves re-routing the digestive system past most of the stomach, so less food is digested and it takes much less to feel full. Gastric sleeve involves removing some of the stomach to reduce the amount of food that's required to feel full. Obesity causes changes in the bacteria that live in the gut (microbiota). After bariatric surgery there are changes in the gut microbiota and in intestinal hormones (e.g. GLP-1) that control satiety (fullness) and food intake. Although gut microbiota changes have been suggested to alter levels of GLP-1, the mechanism and its importance in bariatric surgery remain to be determined. The aim of this study is to investigate the changes in the gut microbiota after two different types of bariatric surgery, as well as the relationship with blood levels of GLP-1.

Who can participate?

Women aged 18-65 who are severely obese and not diabetic

What does the study involve?

Participants are randomly allocated into two groups to undergo either gastric bypass or gastric sleeve surgery. Participants are followed for 6 months after surgery, and fecal and blood samples are collected before surgery as well as 3 and 6 months after surgery. Meal-stimulated blood GLP-1 levels are measured before and 3 and 6 months after surgery.

What are the possible benefits and risks of participating?

This study may increase knowledge of the mechanisms controlling obesity and help develop better and less invasive treatments, as well as providing more information regarding the

participant's own outcome of surgery and a more extensive follow-up after surgery. The risks of participating can be considered low as participation only involves repeated blood sampling.

Where is the study run from? Södertälje Sjukhus AB (Sweden)

When is the study starting and how long is it expected to run for? February 2017 to September 2020

Who is funding the study?
1. Mats Kleberg Foundation (Sweden)
2. Fredrik och Ingrid Thurings Stiftelse (Sweden)
3. Tore Nilsons Stiftelse för Medicinsk Forskning (Sweden)

Who is the main contact? Dr Camilla Krizhanovskii

Contact information

Type(s) Scientific

Contact name Dr Camilla Krizhanovskii

ORCID ID http://orcid.org/0000-0003-2195-165X

Contact details Lagmansvägen 15 Södertälje Sweden 15286

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers nr1

Study information

Scientific Title

Characterization of the incretin response and microbiota in women before an after bariatric surgery, aiming to determine how the microbiota regulates metabolism, and its role for weight loss: a randomized controlled trial

Study objectives

Alteration of gut microbiota following bariatric surgery contributes to its efficacy as a weight loss treatment through modulation of the secretion of the anorectic hormone GLP-1.

Ethics approval required Old ethics approval format

Ethics approval(s)

Regionala etikprövningsnämnden i Stockholm (regional ethics board in Stockholm), 26/08/2015, ref: 2015/795-31/2

Study design Randomized controlled trial

Primary study design Interventional

Secondary study design Randomised controlled trial

Study setting(s) Hospital

Study type(s) Treatment

Participant information sheet No participant information sheet available

Health condition(s) or problem(s) studied Obesity

Interventions

Non-diabetic patients with severe obesity (that is, BMI >40 kg/m. or BMI >35 kg/m. with comorbidities) will be randomized into two groups receiving either gastric bypass (RYGB) or gastric sleeve. Patients will be followed for 6 months post-surgery, and fecal and blood samples will be collected before surgery, as well as 3 and 6 months after surgery. Meal stimulated GLP-1 plasma levels will be determined prior to and 3 and 6 months after surgery. The primary endpoint is the proportion of subjects achieving a 15% relative change in meal stimulated GLP-1 plasma levels following gastric bypass surgery (RYGB)/gastric sleeve compared to pre-surgical meal stimulated GLP-1 release, as assessed by GLP-1 specific ELISA of serum samples. Secondary endpoints are whether a 15% weight reduction of presurgical body weight is observed following gastric bypass surgery (RYGB)/sleeve.

Intervention Type

Procedure/Surgery

Primary outcome measure

1. Plasma GLP-1, measured using the meal tolerance test and GLP-1 specific ELISA of serum samples

2. Gut microbiota composition, analyzed from fecal samples

Timepoints: before 10-day diet, after 10-day diet/before surgery, 3 months after surgery, 6 months after surgery

Secondary outcome measures

1. Plasma inflammatory markers, analyzed by specific ELISAs

2. Lipid profile, determined by commercially available HDL and LDL/VLDL Cholesterol Assay Kits, Free Fatty Acid Quantification Kit, as well as Triglyceride Quantification Kit

Timepoints: before 10-day diet, after 10-day diet/before surgery, 3 months after surgery, 6 months after surgery

Overall study start date

01/10/2016

Completion date

01/09/2020

Eligibility

Key inclusion criteria

1. Obese non-diabetic females 2. 18-65 years of age

3. Signed informed consent form

Participant type(s)

Patient

Age group Adult

Lower age limit 18 Years

Upper age limit 65 Years

Sex Female

Target number of participants 30 subjects (15 in each group)

Key exclusion criteria

Type 2 diabetes
 Any history of receiving GLP-1 analogues or DPP-4 inhibitors

3. Previous treatment with insulin (any regimen) within 3 months

4. Current or history of drug and alcohol abuse

Date of first enrolment 27/02/2017

Date of final enrolment 30/03/2020

Locations

Countries of recruitment Sweden

Study participating centre Södertälje Sjukhus AB Sweden 15286

Sponsor information

Organisation Södertälje Sjukhus

Sponsor details Lagmansvägen 15 Södertälje Sweden 15286

Sponsor type Hospital/treatment centre

ROR https://ror.org/0376t7t08

Funder(s)

Funder type Charity

Funder Name

Mats Kleberg Foundation

Funder Name Fredrik och Ingrid Thurings Stiftelse

Alternative Name(s) Fredrik and Ingrid Thurings Foundation

Funding Body Type Private sector organisation

Funding Body Subtype Trusts, charities, foundations (both public and private)

Location Sweden

Funder Name Tore Nilsons Stiftelse för Medicinsk Forskning

Alternative Name(s) Tore Nilsson Foundation, Tore Nilsson Fond

Funding Body Type Private sector organisation

Funding Body Subtype Trusts, charities, foundations (both public and private)

Location Sweden

Results and Publications

Publication and dissemination plan Planned publication in a high-impact peer reviewed journal

Intention to publish date 30/11/2020

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study are/will be available upon request from Camilla Krizhanovskii

IPD sharing plan summary Available on request